Studies in patients with primary breast cancer have shown that there is a correlation between the presence of FGFR4 polymorphism (FGFR4-Gly388Arg) and tumor aggressiveness and poor response to adjuvant CMF chemotherapy (cyclophosphamide/methotrexate/5-fluorouracil) but not to endocrine therapy or NCT (neoadjuvant chemotherapy consisting of doxorubicin, cyclophosphamide, docetaxel, and pemetrexed) [179,180,181]. The gene discussed is FGFR4; the disease is neoplasm.